FI842615A0 - Analoger av mevalolakton och deras de- rivat, foerfarande foer producering av dessa, dessa innehaollande farmaceutiska kompositioner och deras anvaendning. - Google Patents

Analoger av mevalolakton och deras de- rivat, foerfarande foer producering av dessa, dessa innehaollande farmaceutiska kompositioner och deras anvaendning.

Info

Publication number
FI842615A0
FI842615A0 FI842615A FI842615A FI842615A0 FI 842615 A0 FI842615 A0 FI 842615A0 FI 842615 A FI842615 A FI 842615A FI 842615 A FI842615 A FI 842615A FI 842615 A0 FI842615 A0 FI 842615A0
Authority
FI
Finland
Prior art keywords
hydrogen
dessa
och deras
benzyloxy
phenoxy
Prior art date
Application number
FI842615A
Other languages
English (en)
Other versions
FI77228B (fi
FI77228C (fi
FI842615A (fi
Inventor
Faizulla Gulamhusein Kathawala
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of FI842615A0 publication Critical patent/FI842615A0/fi
Publication of FI842615A publication Critical patent/FI842615A/fi
Publication of FI77228B publication Critical patent/FI77228B/fi
Application granted granted Critical
Publication of FI77228C publication Critical patent/FI77228C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI842615A 1982-11-22 1984-06-28 Foerfarande foer framstaellning av farmaceutiskt anvaendbara indolderivat. FI77228C (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44366882A 1982-11-22 1982-11-22
US44366882 1982-11-22
US54885083A 1983-11-04 1983-11-04
US54885083 1983-11-04
PCT/EP1983/000308 WO1984002131A1 (en) 1982-11-22 1983-11-18 Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
EP8300308 1983-11-18

Publications (4)

Publication Number Publication Date
FI842615A0 true FI842615A0 (fi) 1984-06-28
FI842615A FI842615A (fi) 1984-06-28
FI77228B FI77228B (fi) 1988-10-31
FI77228C FI77228C (fi) 1989-02-10

Family

ID=27033614

Family Applications (1)

Application Number Title Priority Date Filing Date
FI842615A FI77228C (fi) 1982-11-22 1984-06-28 Foerfarande foer framstaellning av farmaceutiskt anvaendbara indolderivat.

Country Status (18)

Country Link
EP (1) EP0114027B1 (fi)
JP (1) JPH0347167A (fi)
AT (1) ATE31718T1 (fi)
AU (1) AU570021B2 (fi)
CA (1) CA1210405A (fi)
CY (1) CY1579A (fi)
DE (2) DE3375137D1 (fi)
DK (2) DK359284A (fi)
FI (1) FI77228C (fi)
GR (1) GR79042B (fi)
HK (1) HK11191A (fi)
HU (1) HU204253B (fi)
IE (1) IE56262B1 (fi)
IL (1) IL70286A (fi)
LU (1) LU88670I2 (fi)
NL (1) NL950022I2 (fi)
NZ (1) NZ206338A (fi)
WO (1) WO1984002131A1 (fi)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
JPS62501009A (ja) * 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
WO1987002662A2 (en) * 1985-10-25 1987-05-07 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
NZ221717A (en) * 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4904646A (en) * 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
EP0326386A3 (en) * 1988-01-27 1990-04-25 May & Baker Limited Isoquinolinones
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
ATE99281T1 (de) * 1988-10-13 1994-01-15 Sandoz Ag Verfahren zur herstellung von 7-substituierten hept-6-en- und heptansaeuren und derivaten davon.
JPH04270285A (ja) * 1988-11-14 1992-09-25 Nissan Chem Ind Ltd ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) * 1989-08-22 1989-10-04 Fujisawa Pharmaceutical Co Pyrroloquinoline compounds
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
JP2736599B2 (ja) * 1993-07-23 1998-04-02 株式会社キッツ ボールバルブのシート構造
US6425881B1 (en) 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
ES2194202T3 (es) * 1996-06-24 2003-11-16 Novartis Ag Compuestos polimorfos.
EP0988289A2 (en) 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2003535077A (ja) 2000-05-26 2003-11-25 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド インドール誘導体を製造する方法、および該方法の中間体
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
KR20040018359A (ko) 2001-04-18 2004-03-03 젠자임 코포레이션 지방족 폴리아민으로 ｘ 증후군을 치료하는 방법
CA2454072A1 (en) * 2001-08-03 2003-02-20 Paul Adriaan Van Der Schaaf Crystalline forms of fluvastatin sodium
ATE521599T1 (de) 2001-12-21 2011-09-15 X Ceptor Therapeutics Inc Heterocyclische modulatoren von nukleären rezeptoren
AU2003230835A1 (en) 2002-04-12 2003-10-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) * 2003-08-27 2008-07-23 住友化学株式会社 芳族不饱和化合物的制备方法
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
KR20070085874A (ko) * 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
CN104188952A (zh) 2005-03-02 2014-12-10 默沙东公司 抑制组织蛋白酶k的组合物
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
US8354530B2 (en) 2005-07-28 2013-01-15 Lek Pharmaceuticals d. d Process for the synthesis of rosuvastatin calcium
WO2007059372A2 (en) 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
WO2007121484A2 (en) 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
DE602006006899D1 (de) 2006-04-20 2009-07-02 Italiana Sint Spa Verfahren zur Herstellung von Fluvastatin-Natrium
ME01901B (me) 2006-07-05 2014-12-20 Astrazeneca Ab Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2435410T1 (sl) 2009-05-28 2017-06-30 Bristol-Myers Squibb Company Lxr modulatorji
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CA2791613A1 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
CN103153299A (zh) 2010-10-06 2013-06-12 国立大学法人东京大学 淋巴水肿预防治疗剂
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140108705A (ko) 2011-12-29 2014-09-12 트러스티즈 오브 터프츠 칼리지 재생 및 염증 반응을 제어하기 위한 생체물질의 기능화
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
RU2692799C2 (ru) 2013-10-08 2019-06-27 Мерк Шарп И Доум Корп. Ингибиторы цистеинпротеаз катепсинов
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
CA2927920A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases

Also Published As

Publication number Publication date
DK97890A (da) 1990-04-19
GR79042B (fi) 1984-10-02
NZ206338A (en) 1987-08-31
CA1210405A (en) 1986-08-26
DK165244B (da) 1992-10-26
DK165244C (da) 1993-03-22
HU204253B (en) 1991-12-30
DK359284D0 (da) 1984-07-20
IE56262B1 (en) 1991-06-05
AU570021B2 (en) 1988-03-03
DK359284A (da) 1984-07-20
NL950022I2 (nl) 1996-12-02
FI77228B (fi) 1988-10-31
FI77228C (fi) 1989-02-10
JPH0347167A (ja) 1991-02-28
ATE31718T1 (de) 1988-01-15
DE3375137D1 (en) 1988-02-11
IL70286A (en) 1987-08-31
LU88670I2 (fr) 1996-04-29
DK97890D0 (da) 1990-04-19
EP0114027B1 (en) 1988-01-07
IE832713L (en) 1984-05-22
WO1984002131A1 (en) 1984-06-07
FI842615A (fi) 1984-06-28
JPH0440343B2 (fi) 1992-07-02
CY1579A (en) 1991-12-20
NL950022I1 (fi) 1996-01-02
DE19475017I2 (de) 2003-02-20
HK11191A (en) 1991-02-13
EP0114027A1 (en) 1984-07-25
AU2261283A (en) 1984-06-18
IL70286A0 (en) 1984-02-29
HUT35642A (en) 1985-07-29

Similar Documents

Publication Publication Date Title
FI842615A0 (fi) Analoger av mevalolakton och deras de- rivat, foerfarande foer producering av dessa, dessa innehaollande farmaceutiska kompositioner och deras anvaendning.
NZ214402A (en) Indene derivatives and pharmaceutical compositions
ES8102561A1 (es) Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
AU570942B2 (en) Analogs of mevalonolactone and derivatives thereof, processesfor their production, pharmaceutical compositions containing them and their use as pharmaceuticals
DE3067201D1 (en) Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them
ES2010284A6 (es) Procedimiento para preparar derivados de tiourea.
IL61769A0 (en) 2-phenylamino-imidazolines-(2),their preparation and pharmaceutical compositions containing them
EP0086756A3 (en) Dermatological compositions based on mercaptopropionylamidoacetic thiol esters

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L67

Extension date: 20080823

ND Supplementary protection certificate (spc) granted
PC Transfer of assignment of patent

Owner name: NOVARTIS AG

MA Patent expired

Owner name: NOVARTIS AG